290 - Dendron-functionalized polymeric nanoparticles for cocktail therapy of advanced prostate cancer
Rakesh Kumar Pathak, firstname.lastname@example.org, Shanta Dhar. Chemistry, University of Georgia, Athens, Georgia 30602, United States
Prostate cancer (PCa) is one of the lethal forms of cancer that initially grows in the prostate gland.1 Androgen ablation/castration therapy has been used extensively as anticancer modality for the initial stage of this disease. PCa that progresses even in the presence of androgen ablation is defined as Castration-Resistant Prostate Cancer (CRPC).2 At this stage PCa tends to spreads from its original place to another part of the body, such as bones, and lymph nodes and
this stage of PCa further defined as metastatic PCa and it affects more than 80% of CRPC patients.3 Cancer-associated inflammation functionally plays an important role in the formation of metastasis. Treatment of CRPC primarily relies on the use of cytotoxic chemotherapy following hormonal manipulation. However, chemotherapeutic agents do not help to relieve many of the symptoms related with CRPC, such as chronic inflammation and bone metastases.
Recently anti-inflammatory drugs have been used as adjuvant for chemotherapy for the treatment of metastasis PCa.4 However the choice of correct drug combination and its synergistic ratio are ill defined. By combining controlled release polymer technology and targeted drug delivery approaches, we aim to differentially deliver chemotherapeutic drugs to PCa cells along with synergistic anti-inflammatory agents and inhibitors of bone resorption in a temporally regulated manner resulting in safer and more effective management of deadly CRPC. Polymeric NPs of dual drug functionalized polylactide (PLA) and poly(lactide-co-glycolide)-b-polyethyleneglycol (PLGA-b-PEG) block copolymers demonstrate significant better cytotoxic profile as compared to that of individual drugs.
References[ol][li]Prostate cancer NIH Publication No. 12-1576.[/li][li]Fujimoto, N.; Shiota, M.; Kubo, T.; Matsumoto, T. Expert Rev. Clin. Pharmacol. 2010 , 3, 785-795.[/li][li]Sturge, J.; Caley, M. P.; Waxman, J. Nat. Rev. Clin. Oncol. 2011 , 8, 357-368.[/li][li]Jia, J.; Zhu, F.; Ma, X.; Cao, Z.; Li, Y.; Chen, Y. Z. Nat Rev Drug Discov 2009 , 8, 111-128.[/li][/ol]
Wednesday, March 19, 2014 07:00 PM
General Poster Session (07:00 PM - 10:00 PM)
Location: Dallas Convention Center
Room: Ballroom A